journal
https://read.qxmd.com/read/38117424/clinical-and-genotype-characteristics-and-symptom-migration-in-patients-with-mixed-phenotype-transthyretin-amyloidosis-from-the-transthyretin-amyloidosis-outcomes-survey
#21
JOURNAL ARTICLE
Juan González-Moreno, Angela Dispenzieri, Martha Grogan, Teresa Coelho, Ivailo Tournev, Márcia Waddington-Cruz, Jonas Wixner, Igor Diemberger, Pablo Garcia-Pavia, Doug Chapman, Pritam Gupta, Oliver Glass, Leslie Amass
INTRODUCTION: Transthyretin amyloidosis (ATTR amyloidosis) is primarily associated with a cardiac or neurologic phenotype, but a mixed phenotype is increasingly described. METHODS: This study describes the mixed phenotype cohort in the Transthyretin Amyloidosis Outcomes Survey (THAOS). THAOS is an ongoing, longitudinal, observational survey of patients with ATTR amyloidosis, including both hereditary (ATTRv) and wild-type disease, and asymptomatic carriers of pathogenic transthyretin variants...
December 20, 2023: Cardiology and Therapy
https://read.qxmd.com/read/38062285/automatic-quantification-of-local-plaque-thickness-differences-as-assessed-by-serial-coronary-computed-tomography-angiography-using-scan-quality-based-vessel-specific-thresholds
#22
JOURNAL ARTICLE
Finn Y van Driest, Alexander Broersen, Rob J van der Geest, J Wouter Jukema, Arthur J H A Scholte, Jouke Dijkstra
INTRODUCTION: The use of serial coronary computed tomography angiography (CCTA) allows for the early assessment of coronary plaque progression, a crucial factor in averting major adverse cardiac events (MACEs). Traditionally, serial CCTA is assessed using anatomical landmarks to match baseline and follow-up scans. Recently, a tool has been developed that allows for the automatic quantification of local plaque thickness differences in serial CCTA utilizing plaque contour delineation. The aim of this study was to determine thresholds of plaque thickness differences that define whether there is plaque progression and/or regression...
December 7, 2023: Cardiology and Therapy
https://read.qxmd.com/read/38055177/impact-of-access-site-on-periprocedural-bleeding-and-cerebral-and-coronary-events-in-high-bleeding-risk-percutaneous-coronary-intervention-findings-from-the-riva-pci-trial
#23
JOURNAL ARTICLE
Martin Borlich, Uwe Zeymer, Harm Wienbergen, Hans-Peter Hobbach, Alessandro Cuneo, Raffi Bekeredjian, Oliver Ritter, Birgit Hailer, Klaus Hertting, Marcus Hennersdorf, Werner Scholtz, Peter Lanzer, Harald Mudra, Markus Schwefer, Peter-Lothar Schwimmbeck, Christoph Liebetrau, Holger Thiele, Christoph Claas, Thomas Riemer, Ralf Zahn, Leon Iden, Gert Richardt, Ralph Toelg
INTRODUCTION: The preference for using transradial access (TRA) over transfemoral access (TFA) in patients requiring percutaneous coronary intervention (PCI) is based on evidence suggesting that TRA is associated with less bleeding and fewer vascular complications, shorter hospital stays, improved quality of life, and a potential beneficial effect on mortality. We have limited study data comparing the two access routes in a patient population with atrial fibrillation (AF) undergoing PCI, who have a particular increased risk of bleeding, while AF itself is associated with an increased risk of thromboembolism...
December 6, 2023: Cardiology and Therapy
https://read.qxmd.com/read/38055176/dual-pathway-inhibition-with-rivaroxaban-and-low-dose-aspirin-does-not-alter-immune-cell-responsiveness-and-distribution-in-patients-with-coronary-artery-disease
#24
JOURNAL ARTICLE
Laszlo A Groh, Loes H Willems, Paula Fintelman, Michel M P J Reijnen, Saloua El Messaoudi, Michiel C Warlé
INTRODUCTION: Cardiovascular diseases (CVD) are the leading cause of death globally. Inflammation is an important driver of CVD where tissue damage may lead to the formation of deadly thrombi. Therefore, antithrombotic drugs, such as platelet inhibitors, are crucial for secondary risk prevention in coronary artery disease (CAD) and peripheral artery disease (PAD). For severe forms of the disease, dual-pathway inhibition (DPI) where low-dose aspirin is combined with rivaroxaban has shown improved efficacy in reducing cardiovascular mortality...
December 6, 2023: Cardiology and Therapy
https://read.qxmd.com/read/37668939/contemporary-use-of-coronary-physiology-in-cardiology
#25
REVIEW
Ayman Elbadawi, Ramy Sedhom, Mohamed Ghoweba, Abdelazeem Mohamed Etewa, Waleed Kayani, Faisal Rahman
Coronary angiography has a limited ability to predict the functional significance of intermediate coronary lesions. Hence, physiological assessment of coronary lesions, via fractional flow reserve (FFR) or instantaneous wave-free ratio (iFR), has been introduced to determine their functional significance. An accumulating body of evidence has consolidated the role of physiology-guided revascularization, particularly among patients with stable ischemic heart disease. The use of FFR or iFR to guide decision-making in patients with stable ischemic heart disease and intermediate coronary lesions received a class I recommendation from major societal guidelines...
December 2023: Cardiology and Therapy
https://read.qxmd.com/read/37979080/application-of-hydrogels-in-cardiac-regeneration
#26
REVIEW
Xuejing Yu
Myocardial infarction (MI) is a leading cause of death globally. Due to limited cardiac regeneration, infarcted myocardial tissue is gradually replaced by cardiac fibrosis, causing cardiac dysfunction, arrhythmia, aneurysm, free wall rupture, and sudden cardiac death. Thus, the development of effective methods to promote cardiac regeneration is extremely important for MI treatment. In recent years, hydrogels have shown promise in various methods for cardiac regeneration. Hydrogels can be divided into natural and synthetic types...
November 18, 2023: Cardiology and Therapy
https://read.qxmd.com/read/37950144/podcast-on-self-administered-intranasal-etripamil-for-symptomatic-paroxysmal-supraventricular-tachycardia-the-rapid-trial
#27
LETTER
Bruce S Stambler, James E Ip
Paroxysmal supraventricular tachycardia (PSVT) is commonly seen in clinical practice and represents a significant burden to the healthcare system and to patients. First-line treatments include calcium channel blockers (CCB), although they are intravenous and require medical supervision. Etripamil is an investigational self-administered intranasal L-type CCB for unsupervised treatment of PSVT. In this podcast, we discuss the RAPID trial (NCT03464019), which was a phase 3 study that evaluated the safety and efficacy of etripamil in terminating PSVT episodes using a repeat-dosing regimen...
November 10, 2023: Cardiology and Therapy
https://read.qxmd.com/read/37947939/cardiovascular-compatibility-of-proton-pump-inhibitors-practice-recommendations
#28
JOURNAL ARTICLE
Jamshed Dalal, Anjan Lal Dutta, Jagdish Hiremath, Shamanna Seshadri Iyengar, Jagadish Chander Mohan, Abraham Ooman, Bhabadev Goswami, Kotacherry Thrivikrama Shenoy
This manuscript aims to critically evaluate the current evidence regarding adverse cardiovascular effects associated with proton pump inhibitors (PPIs) in patients with coronary artery disease (CAD). It also provides guidance for the selection of the most appropriate PPI within the context of cardiovascular polypharmacy and emphasizes the importance of establishing consensus among clinicians on the need to prescribe PPIs with limited cytochrome P450 (CYP450) enzyme inhibition to reduce the risk of drug interactions...
November 10, 2023: Cardiology and Therapy
https://read.qxmd.com/read/37938523/left-atrial-appendage-closure-a-narrative-review
#29
REVIEW
Takashi Nagasaka, Mamoo Nakamura
Atrial fibrillation (AF) is the most common cardiac arrhythmia and the cause of thromboembolic events in elderly patients worldwide. AF is associated with a significantly increased risk of morbidity and mortality due to cardiac emboli, primarily from left atrial appendage (LAA) thrombus. Oral anticoagulation therapy is the standard treatment to effectively reduce the risk of thromboembolic events in patients with AF. However, anticoagulation treatment increases bleeding risk. LAA closure (LAAC) has recently been introduced as a feasible mechanical preventive intervention for thromboembolic events while minimizing the risk of bleeding...
November 8, 2023: Cardiology and Therapy
https://read.qxmd.com/read/37864121/comparative-effectiveness-of-various-radiofrequency-ablation-catheters-in-the-ablation-of-typical-atrial-flutter
#30
JOURNAL ARTICLE
Asher Gorantla, Mahmoud Alsaiqali, Jonathan Francois, Shruthi Sivakumar, Leonell Freytes-Santiago, Ahmad Jallad, Adam S Budzikowski
INTRODUCTION: Although ablation of typical atrial flutter (AFL) can be easily achieved with radiofrequency energy (RF), no studies compare the effectiveness of different ablation catheters. Our study aimed to compare the efficacy of various types of ablation catheters in treating typical AFL. METHODS: We analyzed patients with AFL who underwent RF ablation by a single operator at our institution. Successful ablation was evidenced by a bidirectional conduction block (trans-isthmus conduction time ≥ 130 ms or double potentials ≥ 90 ms)...
October 20, 2023: Cardiology and Therapy
https://read.qxmd.com/read/37845427/idarucizumab-for-emergency-reversal-of-the-anticoagulant-effects-of-dabigatran-final-results-of-a-japanese-postmarketing-surveillance-study
#31
JOURNAL ARTICLE
Masahiro Yasaka, Hiroyuki Yokota, Michiyasu Suzuki, Hidesaku Asakura, Teiichi Yamane, Yukako Ogi, Takaaki Kimoto, Daisuke Nakayama
INTRODUCTION: Idarucizumab, a monoclonal antibody fragment that rapidly reverses the anticoagulant effects of dabigatran, was approved in Japan in September 2016, at which time an all-case, postmarketing surveillance (PMS) study was initiated to collect data on idarucizumab in Japanese patients. Interim results were published previously, and the final results are reported herein. METHODS: This multicenter, open-label, uncontrolled, non-interventional PMS study was conducted in Japanese patients who received idarucizumab at the approved dose (2 × 2...
October 17, 2023: Cardiology and Therapy
https://read.qxmd.com/read/37804438/real-world-insights-into-evolocumab-use-in-patients-with-hyperlipidemia-across-five-countries-analysis-from-the-zerbini-study
#32
JOURNAL ARTICLE
Milan Gupta, Rajvi J Wani, Khalid Al Faraidy, Jean Bergeron, Eduardo Contreras, Angel Alberto Garcia Peña, G B John Mancini, Francisco Padilla, Abel Alberto Pavia Lopez, Kiran Philip, Johnny Wu, Erin S Mackinnon
INTRODUCTION: This study characterizes patients receiving evolocumab in clinical practice and assesses treatment effectiveness, safety and persistence outcomes across five countries. METHODS: This retrospective and prospective observational study enrolled patients initiated on evolocumab during August 2017 to July 2019 at 49 sites across Canada, Mexico, Colombia, Saudi Arabia and Kuwait. Medical records data were extracted within 6 months prior to (baseline) and every 3 months for 12 months post evolocumab initiation and reported as available...
October 7, 2023: Cardiology and Therapy
https://read.qxmd.com/read/37803155/evaluation-of-incidence-and-risk-factors-of-sudden-cardiac-death-in-patients-with-chronic-coronary-syndrome-attending-physical-training
#33
JOURNAL ARTICLE
Gergely Galos, Eszter Szabados, Miklos Rabai, Rita Szalai, Luca Anna Ferkai, Ildiko Papp, Kalman Toth, Barbara Sandor
INTRODUCTION: Regular physical activity is recommended to patients with chronic coronary syndrome (CCS). However, vigorous physical exercise occurs as a risk factor of sudden cardiac death (SCD). The effect of short-term and irregular exercise is controversial. The aim of this research is to assess the role of regular training in the incidence of SCD and to identify risk factors among patients with CCS participating in a long-term training program. METHODS: Data of risk factors, therapy, and participation were collected retrospectively for a 10-year period, assessing the length and regularity of participation...
October 6, 2023: Cardiology and Therapy
https://read.qxmd.com/read/37789237/antiplatelet-treatment-patterns-and-outcomes-for-secondary-stroke-prevention-in-the-united-kingdom
#34
JOURNAL ARTICLE
Xuejun Liu, Jenny Jiang, Danshi Li, Jay Horrow, Hiroshi Tamada, Anja Kahl, Vignesh Hariharan, Ankur Avinav, Xiaoyan Li
INTRODUCTION: Stroke is a leading cause of death and disability worldwide. Antiplatelet therapies are recommended to reduce the risk of recurrent stroke in patients with ischemic stroke/transient ischemic attack (IS/TIA). This study evaluated outpatient antiplatelet treatment patterns and outcomes for secondary stroke prevention (SSP) among UK adults without atrial fibrillation who were hospitalized for IS/TIA. METHODS: This retrospective observational study utilized data from the UK Clinical Practice Research Datalink linked with Hospital Episode Statistics data (01/01/2011-30/06/2019)...
October 4, 2023: Cardiology and Therapy
https://read.qxmd.com/read/37755611/correction-to-epidemiological-study-regarding-the-incidence-of-venous-thromboembolism-in-patients-after-cancer-remission
#35
Miki Imura, Jun Katada, Taro Shiga
No abstract text is available yet for this article.
September 27, 2023: Cardiology and Therapy
https://read.qxmd.com/read/37495769/atrial-arrhythmias-in-adults-with-fontan-palliation
#36
REVIEW
Matthew Laubham, Ben Blais, Anna N Kamp
Single ventricle physiology is a rare form of congenital heart disease and was, historically, a uniformly lethal condition. However, the atriopulmonary Fontan operation, and its successive iterations, the lateral tunnel and extracardiac conduit Fontan, became the fundamental approach to treating single ventricle heart disease. Over time, dysrhythmias are some of the most common complications with Fontan physiology, compounding morbidity and mortality. Atrial arrhythmias are prevalent in the Fontan population and occur in about 15-60% of patients with Fontan palliation, increasingly with age...
September 2023: Cardiology and Therapy
https://read.qxmd.com/read/37382802/practical-recommendations-for-the-use-of-angiotensin-receptor-neprilysin-inhibitors-arni-in-heart-failure-insights-from-indian-cardiologists
#37
REVIEW
Jamshed Dalal, Praveen Chandra, Saumitra Ray, P K Hazra, Jagdish Hiremath, Viveka Kumar, Mahesh K Shah, Jabir Abdullakutty, Debasis Ghosh, Karthik Vasudevan, Panchanan Sahoo
Heart failure is a significant public health concern characterized by notable rates of morbidity and mortality. Despite the presence of guideline-directed medical therapy (GDMT), its utilization remains inadequate. This practical recommendation paper focuses on the utilization of angiotensin receptor-neprilysin inhibitor (ARNI) as a pivotal treatment for heart failure with reduced ejection fraction (HFrEF), heart failure with preserved ejection fraction (HFpEF), and heart failure with improved ejection fraction (HFimpEF)...
September 2023: Cardiology and Therapy
https://read.qxmd.com/read/37261649/short-versus-long-term-dual-antiplatelet-therapy-in-patients-at-high-bleeding-risk-undergoing-pci-in-contemporary-practice-a-systemic-review-and-meta-analysis
#38
JOURNAL ARTICLE
Nader Mankerious, Michael Megaly, Rayyan Hemetsberger, Abdelhakim Allali, Mohamed Samy, Ralph Toelg, Santiago Garcia, Gert Richardt
INTRODUCTION: Patients at high bleeding risk (HBR patients) represent an important subset of patients undergoing percutaneous coronary intervention (PCI). It remains unclear whether a shortened duration of dual antiplatelet therapy (DAPT) confers benefits compared with prolonged duration of DAPT in this patient population. The aim of this study was to investigate and compare bleeding and ischemic outcomes among HBR patients receiving short- versus long-term DAPT after PCI. METHODS: A meta-analysis of studies comparing short-term (1-3 months) and long-term (6-12 months) DAPT after PCI with second-generation drug-eluting stents in HBR patients was performed...
September 2023: Cardiology and Therapy
https://read.qxmd.com/read/37653361/summary-and-comparison-of-the-2022-acc-aha-hfsa-and-2021-esc-heart-failure-guidelines
#39
REVIEW
Sarah Badger, James McVeigh, Praveen Indraratna
The guidelines released by the American College of Cardiology/American Heart Association/Heart Failure Society of America (ACC/AHA/HFSA) in 2022 and those released in 2021 by the European Society of Cardiology (ESC) play a crucial role in offering evidence-based recommendations for the diagnosis and management of heart failure (HF). This comprehensive review aims to provide an overview of these guidelines, incorporating insights from relevant clinical trials. While there is considerable alignment between the two sets of guidelines, certain notable differences arise due to variations in publication timelines, which we will outline...
August 31, 2023: Cardiology and Therapy
https://read.qxmd.com/read/37550542/utility-of-follow-up-echocardiograms-in-uncomplicated-surgical-secundum-atrial-septal-defect-closures-preliminary-analysis
#40
JOURNAL ARTICLE
Ritika Gupta, May Ling Mah, Jessica Bowman, Clifford L Cua
INTRODUCTION: Though less common in the current era, surgical closure of secundum atrial septal defects (ASD2) is still performed in certain clinical situations. Guidelines currently recommend lifelong follow-up with transthoracic echocardiograms (TTE) for patients who have undergone a surgical ASD2 closure. The goal of this study was to determine the utility of follow-up TTE in patients who underwent an uncomplicated ASD2 closure. METHODS: Chart review was performed on patients who had a surgical ASD2 closure between April 1, 1996, and August 30, 2021...
August 7, 2023: Cardiology and Therapy
journal
journal
48935
2
3
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.